This is a kidney condition where parts of the kidney's filtering units get damaged and scarred. It can happen for different reasons. It can start with only some parts of the filters being affected and can progress to affect more of the filters.
Every report comes from a Lived member, sent anonymously.
Have you tried Prednisone for Focal Segmental Glomerulosclerosis?
Focal segmental glomerulosclerosis (FSGS) is scarring in the kidney's tiny filtering units, called glomeruli. "Focal" means only some of the glomeruli are scarred, and "segmental" means only part of each affected glomerulus is damaged. The scarring starts with injury to podocytes, specialized cells that keep protein in the blood from leaking into the urine. The main result is protein loss in the urine, which can make urine look foamy. When the loss is heavy, it can cause nephrotic syndrome: swelling in the legs, around the eyes or throughout the body, weight gain from retained fluid, and low protein levels in the blood. Some people have no symptoms and learn they have FSGS only after a routine urine test. Over time the scarring can reduce how well the kidneys filter blood, and FSGS is a leading cause of kidney failure in both children and adults. FSGS is better understood as a pattern of kidney damage than as one disease. Several different causes produce the same scarring, and identifying which one is behind it is central to choosing treatment.
Doctors group FSGS by its likely cause. In primary FSGS, no outside cause is found, and the damage is thought to come from a substance circulating in the blood that injures the filters. This form often starts suddenly with heavy protein loss. Secondary FSGS develops in response to something else. The kidneys can be overworked when a person has fewer working filtering units than usual (for example, from being born with one kidney or losing kidney tissue) or when the remaining units are under strain, as with severe obesity, sickle cell disease or urine flowing backward from the bladder into the kidneys (reflux nephropathy). Viral infections, especially HIV, can also cause it, as can some medicines and drugs, including certain bisphosphonates given by vein, interferons, anabolic steroids and heroin. When a medicine or drug is responsible, stopping it often lets the kidneys recover at least partly. Genetic FSGS is caused by changes in genes that build the filtering barrier. It is more likely when the disease starts in infancy or childhood, runs in the family, or does not respond to steroids. Separately, variants in a gene called APOL1, which are common in people with recent African ancestry, raise the risk of developing FSGS. This helps explain why FSGS is about five times more common in Black Americans than in white Americans, though most people who carry these variants never develop it. In some people, no cause is found even after a full evaluation.
FSGS usually comes to attention through protein in the urine, swelling, high blood pressure or reduced kidney function on blood tests. Urine tests measure how much protein is leaking, often as a ratio of protein to creatinine (a normal waste product) in a single sample, or as the total collected over 24 hours. Losing more than about 3.5 grams of protein a day is considered nephrotic range. Blood tests check albumin, the main protein the body is losing, and estimated glomerular filtration rate (eGFR), a calculation of how well the kidneys are filtering. A kidney biopsy confirms the diagnosis. A small sample of kidney tissue is taken with a needle and examined under a regular microscope and, ideally, an electron microscope. The electron microscope shows how widespread the podocyte damage is, which helps separate primary FSGS from other forms and rules out look-alike conditions. Because the biopsy shows the pattern but not always the cause, the workup also includes a careful history of medicines, drug use and family kidney disease, plus tests for infections such as HIV and hepatitis. Genetic testing is often recommended when FSGS starts early in life, runs in the family or does not respond to steroids. A negative genetic test does not completely rule out a genetic cause.
Treatment aims to reduce protein leakage and protect kidney function for as long as possible. Lower protein loss is linked to slower kidney decline, so the amount of protein in the urine is the main way doctors judge whether treatment is working. Nearly everyone with FSGS takes a blood pressure medicine from the angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) families, such as lisinopril or losartan. These lower pressure inside the filters and reduce protein leakage in every form of FSGS, but the benefit lasts only while the medicine is taken. A low-sodium diet and water pills (diuretics) help control swelling and blood pressure. For primary FSGS, especially with nephrotic syndrome, treatment usually adds a course of steroids such as prednisone, often for several months. When steroids do not work or are not tolerated, calcineurin inhibitors (immune-suppressing medicines such as tacrolimus or cyclosporine) are the usual next step. These treatments can bring protein loss down or into remission, but they suppress the immune system and carry real side effects, so they are used only when the evidence points to primary FSGS. They generally do not help secondary, genetic or unexplained FSGS, where treatment focuses on blood pressure, protein reduction and the underlying cause, such as stopping a responsible drug or treating HIV. In 2026 the FDA approved sparsentan (Filspari), a pill that blocks two hormone pathways that raise pressure in the filters, for people aged 8 and older with FSGS who do not have nephrotic syndrome. In a two-year trial it lowered protein loss more than the ARB irbesartan, but it did not clearly slow the decline in kidney function over that period. It requires liver blood tests before starting and every three months, it is available only through a restricted program, and it cannot be taken during pregnancy because it can harm a developing baby. If the kidneys fail, dialysis or a kidney transplant replaces their work.
The course of FSGS varies widely and depends a great deal on the cause and on how much protein loss can be reduced. People whose protein levels fall substantially with treatment tend to keep their kidney function much longer. Heavy protein loss that does not respond to treatment carries a higher risk of reaching kidney failure. A large share of people with FSGS eventually develop chronic kidney disease or kidney failure, but the timeline differs greatly from person to person. Day to day, people describe swelling, fatigue, weight changes and disrupted sleep, along with the side effects of treatment, particularly steroids. Managing salt intake, taking medicines consistently and getting regular urine and blood tests become part of ordinary life. Regular follow-up with a nephrologist (kidney specialist) tracks protein levels and kidney function, with closer checks when treatment is being started or changed. People with nephrotic syndrome are more prone to infections. For people who reach kidney failure, a kidney transplant is one option alongside dialysis. Primary FSGS can return in the new kidney, sometimes soon after surgery, so transplant teams monitor protein closely and may use treatments that filter the blood (plasma exchange) if it recurs. Genetic FSGS does not come back in a transplanted kidney.
See a clinician if you notice persistently foamy urine, new swelling in your legs, ankles or around your eyes, or unexplained weight gain, or if a routine test shows protein in your urine. These can have several causes, but they are worth checking. If you already have FSGS, contact your care team promptly about a fever or other signs of infection, pain when urinating, noticeably less urine than usual, or swelling or weight gain that is getting worse despite treatment. Let them know right away if you become pregnant or are planning pregnancy, since some FSGS medicines, including sparsentan, cannot be taken during pregnancy.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Focal Segmental Glomerulosclerosis is like, what's helped you, or ask the community a question.